Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6817
Source ID: NCT00506298
Associated Drug: Bezafibrate + Diflunisal
Title: Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes
Interventions: DRUG: bezafibrate + diflunisal|DRUG: bezafibrate + placebo
Outcome Measures: Primary: The primary efficacy endpoint will measure change in fasting plasma glucose from Baseline to Day 90, Day 90 | Secondary: The exploratory efficacy endpoints will measure change in the following parameters: HOMA Index, HgbA1C, fructosamine, LDL, HDL, OGTT, triglycerides and total cholesterol from Baseline to Day 90, Day 90
Sponsor/Collaborators: Sponsor: Zalicus
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 150
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2007-07
Completion Date: 2009-05
Results First Posted:
Last Update Posted: 2009-05-13
Locations: Chilliwack, British Columbia, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Bay Roberts, Newfoundland and Labrador, Canada|Holyroad, Newfoundland and Labrador, Canada|St. Johns, Newfoundland and Labrador, Canada|Aylmer, Ontario, Canada|Burlington, Ontario, Canada|Collingwood, Ontario, Canada|Corunna, Ontario, Canada|Robarts Research Institute, London, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Sarnia, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Saskatoon, Saskatchewan, Canada
URL: https://clinicaltrials.gov/show/NCT00506298

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D381 Bezafibrate small molecule DB01393 Details
D249 Diflunisal small molecule DB00861 Details